Boehringer Ingelheim and CDR-Life Deepen Collaboration to Advance Autoimmune Drug Development

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases

Boehringer has licensed CDR111 from CDR-Life, an antibody-based trispecific M-gager® for autoimmune diseases. ...

Boehringer and CDR-Life announce licensing deal for autoimmune disease therapy

Boehringer Ingelheim and CDR-Life have announced a worldwide licencing agreement for the development of CDR111, an antibody-based molecule targeting autoimmune conditions.

Boehringer Ingelheim and CDR-Life Deepen Collaboration to Advance Autoimmune Drug Development

Open the article to view the coverage from EuropaWire.eu

Boehringer Ingelheim in US$570m deal with CDR-Life - European Biotechnology Magazine

Boehringer Ingelheim has licenced global rights for CDR111, an antibody-based trispecific M-gager to treat autoimmune diseases from  CDR-Life, Inc. CDR111 is an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset.   The post Boehringer Ingelheim in US$570m deal with CDR-Life appeared first on European Biotechnology Magazine.

Swiss biotech returns to Boehringer Ingelheim to partner on autoimmune T cell engager

CDR-Life has inked a second licensing pact with Boehringer Ingelheim, as the Zurich-based startup will work with the German drug company in a ripe area of dealmaking. For 38 million Swiss francs (about $48 million) ...